Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Outcome of Non-Critical COVID-19 Patients with Early Hospitalization and Early Antiviral Treatment Outside the ICU

BaŞaran et al., Turk. J. Med. Sci., doi:10.3906/sag-2006-173
Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Observational study of 174 hospitalized patients in Turkey, median age 45.4, 23 treated with HCQ, 113 with HCQ+AZ, and 32 with regimens including favipiravir. 75% reduction in the median time to clinical improvement for HCQ+AZ vs. FAV, RR 0.25, p<0.001. 83% reduction for HCQ. However, there was significant confounding by indication.
There were no significant adverse events.
BaŞaran et al., 28 Jul 2020, prospective, Turkey, peer-reviewed, 18 authors.
This PaperHCQAll
Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU
Nursel Çalik Başaran, Oğuz Abdullah Uyaroğlu, Gülçin Telli Dizman, Lale Özişik, Taha Koray Şahin, Zahit Taş, Ahmet Çağkan İnkaya, Sevilay Karahan, Şehnaz Alp, Alpaslan Alp, Gökhan Metan, Pınar Zarakolu, Gülay Sain Güven, Şerife Gül Öz, Arzu Topeli, Ömrüm Uzun, Murat Akova, Serhat Ünal
TURKISH JOURNAL OF MEDICAL SCIENCES, doi:10.3906/sag-2006-173
World Health Organization (2020) . Coronavirus Disease (COVID-19) Situation Report [online]. Website: https://www.who.int/docs/default-source/ coronaviruse/situation-reports/ 20200513-covid-19-sitrep-114.pdf?sfvrsn=17ebbbe_4 [accessed 06 06 2020]. Turkey ranks at 12 in the list of countries with the highest number of cases, with a total number of infected patients reaching 170,000, with more than 4000 deaths in the 3 months after the first COVID-19 case was reported Background/aim: Despite the fact that the COVID-19 pandemic has been going on for over 5 months, there is yet to be a standard management policy for all patients including those with mild-to-moderate cases. We evaluated the role of early hospitalization in combination with early antiviral therapy with COVID-19 patients in a tertiary care university hospital. Materials and methods: This was a prospective, observational, single-center study on probable/confirmed COVID-19 patients hospitalized in a tertiary care hospital on COVID-19 wards between March 20 and April 30, 2020. The demographic, laboratory, and clinical data were collected. Results: We included 174 consecutive probable/confirmed COVID-19 adult patients hospitalized in the Internal Medicine wards of the University Adult Hospital between March 20 and April 30, 2020. The median age was 45.5 (19-92) years and 91 patients (52.3%) were male. One hundred and twenty (69%) were confirmed microbiologically, 41 (23.5%) were radiologically diagnosed, and 13 (7.5%) were clinically suspected (negative microbiological and radiological findings compatible with COVID-19); 35 (20.1%) had mild, 107 (61.5%) moderate disease, and 32 (18.4%) had severe pneumonia. Out of 171 cases, 130 (74.3%) showed pneumonia; 80 were typical, and 50 showed indeterminate infiltration for COVID-19. Patients were admitted within a median of 3 days (0-14 days) after symptoms appear. The median duration of hospitalization was 4 days (0-28 days). In this case series, 13.2% patients were treated with hydroxychloroquine alone, 64.9% with hydroxychloroquine plus azithromycin, and 18.4% with regimens including favipiravir. A total of 15 patients (8.5%) were transferred to the ICU. Four patients died (2.2%). Conclusion: In our series, 174 patients were admitted to the hospital wards for COVID-19, 69% were confirmed with PCR and/or antibody test. At the time of admission, nearly one fifth of the patients had severe diseases. Of the patients, 95.4% received hydroxychloroquine alone or in combination. The overall case fatality rate was 2.2%.
References
Cai, Yang, Liu, Chen, Shu, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, doi:10.1016/j.eng.2020.03.007
Chen, Zhou, Dong, Qu, Gong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Farsalinos, Barbouni, Niaura, Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option?, Internal and Emergency Medicine, doi:10.1007/s11739-020-02355-7
Geleris, Sun, Platt, Zucker, Baldwin, Observational study of hydroxychloroquine in hospitalized patients with Covid-19, New England Journal of Medicine, doi:10.1056/NEJMoa2012410
Grasselli, Zangrillo, Zanella, Antonelli, Cabrini, Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, Journal of the American Medical Association, doi:10.1001/jama.2020.5394
Guan, Clinical characteristics of coronavirus disease 2019 in China, The New England Journal of Medicine, doi:10.1056/NEJMoa2002032
Huang, Wang, Li, Ren, Zhao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Li, Chen, Chen, Zhan, Li, Coinfection with SARS-CoV-2 and other respiratory pathogens in COVID-19 patients in Guangzhou, China, Journal of Medical Virology, doi:10.1002/jmv.26073
Mahevas, Tran, Roumer, Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ, doi:10.1136/bmj.m1844
Mavi, İnkaya, COVID-19 Immunopathogenesis, Flora, doi:10.5578/flora.69606
Milliona, Lagiera, Gautreta, Colsona, Fourniera, Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Medicine and Infectious Disease, doi:10.1016/j.tmaid.2020.101738
Myers, Parodi, Escobar, Vincent, Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California, Journal of the American Medical Association
Richardson, Hirsch, Narasimhan, Crawford, Mcginn, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, Journal of the American Medical Association, doi:10.1001/jama.2020.6775
Satman, Omer, Tutuncu, Kalaca, Gedik, Twelveyear trends in the prevalence and risk factors of diabetes and prediabetes in Turkish adults, European Journal of Epidemiology
Tanrıöver, Halaçlı, Sait, Öcal, Topeli, Daily surveillance with early warning scores help predict hospital mortality in medical wards, Turkish Journal of Medical Sciences
Tas, İnkaya, Akova, Current treatment of COVID-19
Wang, Fang, Zhu, Chen, Ding, Clinical characteristics of non-critically ill patients withnovel coronavirus infection (COVID-19) in a Fangcang Hospital, Clinical Microbiology, doi:10.1016/j.cmi.2020.03.032
Yavuz, Ünal, Treatment of COVID19, Turkish Journal of Medical Sciences
Young, Ong, Kalimuddin, Low, Sy, For the Singapore 2019 novel coronavirus outbreak research team. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore, Journal of the American Medical Association, doi:10.1001/jama.2020.3204
Zhang, Cai, Hu, Lian, Gu, Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings, International Journal of Infectious Diseases
Zhang, Dong, Cao, Yuan, Yang, Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China, Allergy, doi:10.1111/all.14238
Zheng, Tang, Li, Huang, Xie, Clinical characteristics of 161 cases of corona virus disease 2019 (Covıd-19) in Changsha, European Review for Medical and Pharmacological Sciences, doi:10.26355/eurrev_202003_20711
Zhu, Ge, Wu, Zhao, Chen, Co-infection with respiratory pathogens among COVID-2019 cases, Virus Res, doi:10.1016/j.virusres.2020.198005
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit